CORDIS
EU research results

CORDIS

English EN
PNEUMOSIP

PNEUMOSIP

Objective

PneumoSIP project aims to be the first fully automated device in the POC market for the fast quantitative aetiological diagnose of Community-Acquired Pneumonia (CAP) also analysing antibiotic resistances to enable the most appropriate treatment for each infected patient.
CAP is known to affect about 1/1,000 of the adult population per year, being even higher in the elderly and children populations. It is the fourth case of death in the world, and the leading cause of death in child population under 5 years old. The causal relationship between pathogens and pneumonia has been clearly established, being Streptococcus pneumoniae, Haemophilus influenzae type b (Hib) and the respiratory syncytial virus (RSV) the main pathogens responsible for CAP in Europe. Antibiotic therapy is the mainstream treatment for CAP, and the appropriate treatment involves starting empiric antibiotics administration within 8 hours of hospital arrival. Given this time constrain, traditional methods for diagnosing the aetiology of CAP have been discarded for CAP guidelines due to the slowness in sample to results. Another complication is that S. pneumoniae is a common colonizer of the nasopharynx (up to 70% of healthy population acts as a host), making the simple detection of the bacteria a useless diagnostic method. Thus, clinicians need rapid and accurate quantitative tests capable of identifying infectious agents and their potential antibiotic resistances.
Therefore, PneumoSIP project aims to be a compact Respiratory Infectious Diseases diagnostic device providing fast quantitative identification of pathogens involved in CAP, enabling faster and more specific treatments. PneumoSIP seeks to combine laboratory standard precision with the simplicity required for POC applications.
The market for PneumoSIP system is the POC market, concretely the Infectious Disease POC testing segment. The POCT segment was valued at $415.4 million in 2012 where Pneumosip will greatly impact.

Coordinator

LABORATORIOS ALPHA SAN IGNACIO PHARMA S.L. - ALPHASIP

Address

Calle Cervantes 40 - 3p - Pc
50006 Zaragoza

Spain

Activity type

Other

EU Contribution

€ 3 389 912,50

Project information

Grant agreement ID: 685052

Status

Closed project

  • Start date

    1 November 2015

  • End date

    28 February 2019

Funded under:

H2020-EU.2.1.3.

H2020-EU.3.1.3.

  • Overall budget:

    € 3 389 912,50

  • EU contribution

    € 3 389 912,50

Coordinated by:

LABORATORIOS ALPHA SAN IGNACIO PHARMA S.L. - ALPHASIP

Spain

This project is featured in...